Key facts
- Notable investors include Delft Enterprises, YES!Delft.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Proteot
- ·The full record, as it builds
Funding rounds
No funding rounds for Proteot are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Proteot
Developer of a therapeutic protein analytics database tool intended for drug development and manufacturing. The company's platform utilizes advanced chemical scaffolds and synthetic polymer technology to maintain the structural integrity and functional activity of sensitive biologics under various environmental stressors, enabling pharmaceutical researchers and biotechnology firms to extend the shelf life of life-saving medications while reducing reliance on complex cold chain logistics and minimizing the risk of molecular degradation.
- Sector
- Healthcare
- HQ
- Delft, Netherlands
- Founded
- 2024
- Employees
- 2
- Website
- proteot.com/
- Ownership
- Privately Held (backing)
Proteot doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Proteot shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Proteot in its N-PORT filings yet. We sweep new filings monthly.